Pro Share Advisors LLC Editas Medicine, Inc. Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 27,252 shares of EDIT stock, worth $52,323. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,252
Previous 20,534 32.72%
Holding current value
$52,323
Previous $70,000 51.43%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$1.2 - $3.76 $8,061 - $25,259
6,718 Added 32.72%
27,252 $34,000
Q3 2024

Nov 13, 2024
BUY
$3.39 - $5.96 $15,048 - $26,456
4,439 Added 27.58%
20,534 $70,000
Q2 2024

Aug 13, 2024
SELL
$4.67 - $7.28 $20,641 - $32,177
-4,420 Reduced 21.55%
16,095 $75,000
Q1 2024

May 08, 2024
BUY
$7.03 - $11.07 $11,817 - $18,608
1,681 Added 8.93%
20,515 $152,000
Q4 2023

Feb 14, 2024
BUY
$6.25 - $11.11 $17,568 - $31,230
2,811 Added 17.54%
18,834 $190,000
Q3 2023

Nov 13, 2023
BUY
$6.92 - $9.31 $17,327 - $23,312
2,504 Added 18.52%
16,023 $124,000
Q2 2023

Aug 10, 2023
BUY
$6.36 - $11.47 $3,854 - $6,950
606 Added 4.69%
13,519 $111,000
Q1 2023

May 11, 2023
SELL
$7.03 - $11.53 $11,697 - $19,185
-1,664 Reduced 11.42%
12,913 $93,000
Q4 2022

Feb 02, 2023
BUY
$8.32 - $13.21 $9,817 - $15,587
1,180 Added 8.81%
14,577 $129,000
Q3 2022

Nov 04, 2022
BUY
$12.16 - $19.42 $3,538 - $5,651
291 Added 2.22%
13,397 $164,000
Q2 2022

Aug 01, 2022
SELL
$9.99 - $21.35 $68,001 - $145,329
-6,807 Reduced 34.18%
13,106 $154,000
Q1 2022

May 10, 2022
SELL
$14.08 - $27.63 $65,640 - $128,811
-4,662 Reduced 18.97%
19,913 $379,000
Q4 2021

Feb 08, 2022
BUY
$26.55 - $40.57 $32,603 - $49,819
1,228 Added 5.26%
24,575 $653,000
Q3 2021

Nov 12, 2021
SELL
$39.27 - $72.94 $258,514 - $480,164
-6,583 Reduced 21.99%
23,347 $959,000
Q2 2021

Aug 13, 2021
BUY
$31.29 - $56.64 $86,986 - $157,459
2,780 Added 10.24%
29,930 $1.7 Million
Q1 2021

May 14, 2021
BUY
$39.71 - $90.58 $143,472 - $327,265
3,613 Added 15.35%
27,150 $1.14 Million
Q4 2020

Feb 09, 2021
BUY
$27.07 - $84.35 $157,114 - $489,567
5,804 Added 32.73%
23,537 $1.65 Million
Q3 2020

Nov 13, 2020
BUY
$28.06 - $37.16 $39,480 - $52,284
1,407 Added 8.62%
17,733 $498,000
Q2 2020

Aug 03, 2020
BUY
$18.5 - $34.34 $115,440 - $214,281
6,240 Added 61.87%
16,326 $483,000
Q1 2020

May 15, 2020
SELL
$14.88 - $32.78 $119,322 - $262,862
-8,019 Reduced 44.29%
10,086 $200,000
Q4 2019

Feb 12, 2020
SELL
$19.49 - $32.63 $18,554 - $31,063
-952 Reduced 5.0%
18,105 $536,000
Q3 2019

Nov 12, 2019
SELL
$22.49 - $26.81 $4,722 - $5,630
-210 Reduced 1.09%
19,057 $433,000
Q2 2019

Aug 13, 2019
SELL
$20.48 - $27.76 $40,960 - $55,520
-2,000 Reduced 9.4%
19,267 $477,000
Q1 2019

May 15, 2019
BUY
$19.43 - $26.41 $4,352 - $5,915
224 Added 1.06%
21,267 $520,000
Q4 2018

Feb 14, 2019
SELL
$18.19 - $31.79 $72,468 - $126,651
-3,984 Reduced 15.92%
21,043 $479,000
Q3 2018

Nov 14, 2018
SELL
$27.65 - $38.39 $22,755 - $31,594
-823 Reduced 3.18%
25,027 $796,000
Q2 2018

Aug 13, 2018
SELL
$31.4 - $41.01 $17,427 - $22,760
-555 Reduced 2.1%
25,850 $926,000
Q1 2018

May 14, 2018
SELL
$29.84 - $44.08 $41,716 - $61,623
-1,398 Reduced 5.03%
26,405 $875,000
Q4 2017

Feb 14, 2018
BUY
$21.89 - $31.34 $44,568 - $63,808
2,036 Added 7.9%
27,803 $854,000
Q3 2017

Nov 13, 2017
BUY
$15.81 - $24.01 $24,600 - $37,359
1,556 Added 6.43%
25,767 $619,000
Q2 2017

Aug 11, 2017
BUY
N/A
24,211
24,211 $406,000

Others Institutions Holding EDIT

# of Institutions
225
Shares Held
54.2M
Call Options Held
412K
Put Options Held
355K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $132M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email